N/A
N=155
Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens
Type 1 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT05280184 ↗Enrolled (actual)
155
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Change in Glycated Hemoglobin- HbA1c — -0.14; -0.09 Change in A1c (%)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Coin2Dose (Behavioral)
- Age
- Pediatric · 11+ yrs
- Sex
- All
- Sponsor
- Nemours Children's Clinic
- Primary completion
- Jun 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Glycated Hemoglobin- HbA1c |
-0.14; -0.09 | — |
| PRIMARY Change in Daily Insulin Bolus Score |
-0.11; -0.08 | — |
| SECONDARY Change in Glucose Time in Range (70-180 mg/dL) |
— | — |
Summary
Our objective is to test the feasibility, acceptability, and initial efficacy of using behavioral economics incentives (BEI) in a novel, semi-automated intervention to target daily insulin BOLUS scores in adolescents with suboptimal insulin use.
Eligibility Criteria
Inclusion Criteria
- adolescents between 11.0-17.0 years old and their parent/guardian;
- adolescents have a physician confirmed diagnosis of type 1 diabetes of at least 6 months duration;
- adolescents use an insulin pump for daily type 1 diabetes self-management;
- adolescents evidence sub-optimal daily BOLUS scores (a mean daily BOLUS score <2.5)
Exclusion Criteria
- adolescents who do not use an insulin pump; adolescents who have an allergy or sensitivity to the adhesive and/or skin preparation used for CGM;
- adolescents with a comorbid chronic condition (e.g., renal disease);
- adolescents and parents who do not speak English
Data sourced from ClinicalTrials.gov (NCT05280184). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.